ArticleFrontiers in endocrinology2026
Dose-, duration- and age-dependent effects of zoledronic acid on bone structure and mechanical properties in growing rice rats.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zoledronic acid (ZOL), a potent bisphosphonate, is increasingly used off-label in pediatric bone disorders, but its long-term effects on the growing skeleton remain underexplored. This study aimed to investigate the impact of ZOL dose, treatment duration, and age at treatment initiation on femoral structure and mechanical properties in growing rice rats, addressing a critical knowledge gap. Methods: Two complementary preclinical studies were performed in female rice rats. Study 1 examined dose-dependent effects by administering ZOL (0, 8, 20, 50, 125 µg/kg) every 4 weeks, starting at age 4 weeks, for up to 30 weeks. Study 2 investigated age at treatment initiation (4, 16, or 22 weeks) and durations (6, 12, or 18 weeks) using a single oncologic dose of ZOL (80 µg/kg every 4 weeks). Femoral cancellous and cortical pQCT assessed bone mineral content (BMC), volumetric bone mineral density (vBMD), area and microstructure. 3-point bending of the femoral diaphysis was used to determine biomechanical properties. Results: ZOL increased total metaphyseal BMC, vBMD, and area, with oncologic doses (20-125 µg/kg) producing 15-25% greater increases in metaphyseal BMC than the osteoporosis dose (8 µg/kg) after 18-30 weeks of treatment. Cortical parameters (area and periosteal circumference) and mid-diaphyseal mechanical properties (ultimate load, moment of inertia) also increased when treatment began in young, growing rats and was maintained for 18-24 weeks, although clear dose-response effects were limited. When ZOL started later, skeletal responses were attenuated and required longer treatment durations to become significant. Conclusions: ZOL enhances metaphyseal and cortical bone properties while improving mechanical strength, particularly when treatment is initiated at an early age. The skeletal response depends on both duration and age at initiation. Notably, ZOL dose-response effects are pronounced in cancellous bone. Cortical structural and mechanical properties exhibit a nonlinear response, with significant differences observed only at extended treatment durations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.